Physostigmine ameliorates the delusions of Alzheimer's disease.
Biol Psychiatry
; 33(7): 536-41, 1993 Apr 01.
Article
en En
| MEDLINE
| ID: mdl-8513039
ABSTRACT
Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a double-blind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Fisostigmina
/
Deluciones
/
Enfermedad de Alzheimer
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Biol Psychiatry
Año:
1993
Tipo del documento:
Article